The Section of Cellular Therapy
Welcome to the Department of Cellular Therapy which is home to one of Europe’s biggest and most modern GMP facilities for cellular products.
Dag Josefsen, MD PhD, Head of Department
(Group leaders: E.M. Inderberg and S. Wälchli) has the capacity to undertake complete pre-clinical studies for immunotherapeutic molecules such as vaccines and adoptive T cell transfer (TCR, CAR). It possesses the competence to deliver molecular biology products isolated from patient material (TCR), to perform cellular assays and in vivo animal studies. Finally, innovative tools are also developed in collaboration with academy and private companies.
The Immunomonitoring Lab (Head: E.M. Inderberg) is a heritage from the former research group of Prof. G. Gaudernack and was included in the Department of Cellular Therapy in 2012. It participated to both academic and industrial trials, more information can be found here.
Our labs are located at the Oslo Cancer Cluster Incubator OCCI
ACT-centre aims at facilitating the development of novel advanced therapy medicinal products (ATMP) and make novel therapies available to Norwegian patients. More information can be found here.
